<DOC>
	<DOCNO>NCT00811499</DOCNO>
	<brief_summary>This Phase 2 study , involve 12-week treatment period , design evaluate effectiveness investigational study drug ARRY-371797 ( versus placebo ) treat ankylose spondylitis , evaluate drug 's safety . Approximately 130 patient US , Canada , Poland Hungary enrol study .</brief_summary>
	<brief_title>A Study ARRY-371797 Patients With Active Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<criteria>Key Diagnosis ankylose spondylitis accord Modified New York Criteria ( 1984 ) . Inadequate response least 2 week continuous treatment NSAIDs , unable receive â‰¥ 2 full week continuous treatment NSAIDs intolerance . If previously treat biological agent , patient must fail due lack efficacy , must complete appropriate washout period prior first dose study drug . Patients may continue specify stable background therapy ankylose spondylitis ( dose stable least 4 week prior first dose study drug ) . Additional criterion exist . Key Diagnosis active uncontrolled inflammatory noninflammatory articular disease may interfere disease activity assessment . Previously treat intravenous immunoglobulin within 6 month prior first dose study drug . Patients require prohibit concomitant medication include moderate strong CYP3A inhibitor , CYP3A inducers Biologic Response Modifiers ( BRMs ) study . Trauma major surgery within 8 week prior first dose study drug . Specific abnormal laboratory value electrocardiogram abnormality . Known positive serology human immunodeficiency virus ( HIV ) , hepatitis C , and/or hepatitis B . Additional criterion exist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>